Remote video URL
Your peers rated this 4 stars
1-minute watch | Talk 1 of 5

ICML: Evolving survival outcomes with CAR T in 2L DLBCL

Series trailer

Trailer for the ICML symposium, entitled 'Evolving survival outcomes with CAR T in 2L DLBCL' featuring Dr Anna Sureda, Clinical Hematology Department, Institut Català d 'Oncologia L'Hospitalet, Barcelona, Spain, Dr Michael Dickinson, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia, Dr Frederick Locke, Moffitt Cancer Center, Tampa, FL, USA, Dr Matthew Lunning, University of Nebraska Medical Center, NE, USA, and Dr Jason Westin, MD Anderson Cancer Center, Houston, Texas, USA

Read more

Talks in this series

Interested in this topic?

Suggested for you

Explore suggested content tailored to your role within the CAR T-cell therapy journey

Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In Great Britain and Northern Ireland, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.